Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Published in: Journal of Cancer Survivorship 4/2012

01-12-2012 | Editorial

Impacting cancer survivorship

Author: Michael Feuerstein

Published in: Journal of Cancer Survivorship | Issue 4/2012

Login to get access

Excerpt

Regardless of the controversy over just what is a cancer survivor, improving the health and daily lives of cancer survivors is of paramount importance. The Journal of Cancer Survivorship: Research and Practice (J CS) was created to help achieve these goals. I have a few announcements that highlight the progress we have made thus far. …
Metadata
Title
Impacting cancer survivorship
Author
Michael Feuerstein
Publication date
01-12-2012
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2012
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-012-0236-8

Other articles of this Issue 4/2012

Journal of Cancer Survivorship 4/2012 Go to the issue

OriginalPaper

The feasibility of psychosocial screening for adolescent and young adult brain tumor survivors: the value of self-report

OriginalPaper

Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study

Policy Papers

The Medical Expenditure Panel Survey (MEPS) Experiences with Cancer Survivorship Supplement

Review

Ethnic disparities in colonoscopy use among colorectal cancer survivors: a systematic review

OriginalPaper

Five-year follow-up of participants in a randomised controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects?

OriginalPaper

Continuity of care of colorectal cancer survivors at the end of treatment: the oncology–primary care interface
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits